TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01696825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam tablet, 5 mg, vaginal
Description: Diazepam tablet, 5 mg, moistened and inserted vaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam tablet, 5 mg, vaginal
Description: Diazepam tablet, 5 mg, moistened and inserted vaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Suppository, 5 mg, vaginal
Description: Compounded diazepam 5 mg suppository administered vaginally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Suppository, 5 mg, vaginal
Description: Compounded diazepam 5 mg suppository administered vaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Cream, 5 mg, Vaginal
Description: Compounded diazepam cream, 5 mg, inserted vaginally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam Cream, 5 mg, Vaginal
Description: Compounded diazepam cream, 5 mg, inserted vaginally
Study: NCT02236975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme Biodegradable drug coating coronary stent system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity durable polymer stent system
Study: NCT00133497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Microfluoridized adjuvant 59 (MF59).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of saline placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine
Description: CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
Study: NCT02077920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving
Study: NCT00585637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Taken orally every day for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Taken orally every day for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Taken orally every day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken once daily for 3 month
Study: NCT01595529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Cephalexin 50mg/kg/day in 3 divided doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the other four active treatments
Study: NCT04769687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prebiotic Orafti®Synergy1
Description: Orafti®Synergy1 is a slightly sweet white powder packaged in 5 g sachets. The dose used is 2 sachets per day (morning and evening) for 8 weeks (56 days).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01595529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: 8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
Study: NCT01862406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Label
Description: Participants were presented with either a generic label or a brand-name label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Participants were presented with either a generic label or a brand-name label
Study: NCT02484443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT02840305

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of visual function

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of visual function

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of visual function

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Study: NCT02077920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving
Study: NCT01668940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lillipop Iced Soothies (Ginger flavour)
Description: Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
Study: NCT02906930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily.
Study: NCT03973112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 3mg/kg
Description: anti-PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 3mg/kg
Description: anti-PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 3mg/kg
Description: anti-PD-1
Study: NCT02906930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration once daily.
Study: NCT01521182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Fermented Dairy Product (test)
Description: 1 = Intervention 1 (test product)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Milk-based non-fermented dairy product (control)
Description: 2 = Intervention 2 (control product)
Study: NCT03750435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation or left-sided AT ablation
Description: According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
Study: NCT00030992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Description: One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2
Study: NCT03086863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
Study: NCT00030992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
Study: NCT02584400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection with the hypoxia tracer [18F]HX4,
Description: The \[18F\]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) \[18F\]HX4 via a bolus IV injection.
Study: NCT00505089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study: NCT01104792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study: NCT00686530

Intervention type: PROCEDURE
Intervention: MR Imaging
Description: Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.

Intervention type: PROCEDURE
Intervention: Autopsy
Description: Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
Study: NCT04112173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perturbation-based fall-recovery training
Description: Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
Study: NCT03709823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film coated tablet containing 1.5 mg cytisine in a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film coated tablet containing 1.5 mg cytisine in a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film coated tablet containing 1.5 mg cytisine in a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film coated tablet containing 1.5 mg cytisine in a single tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 1.5 mg cellulose powder to match final weight of the cytisine tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 1.5 mg cellulose powder to match final weight of the cytisine tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: 12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
Study: NCT00948727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dose adaptation according to CN activity monitoring
Description: The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Description: Cyclosporine (CsA)
Study: NCT01516307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPT-822/OPT-821(30 μg/100 μg)
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Saline (PBS)
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Study: NCT04539886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX System
Description: CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Electrodesiccation
Description: Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
Study: NCT02398773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Given IV
Study: NCT03973112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10 3mg/kg
Description: anti-PD-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 5mg/kg
Description: anti-VEGF, a biosimilar to Avastin
Study: NCT03086863

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
Study: NCT03973112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 10mg/kg
Description: anti-VEGF, a biosimilar to Avastin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04 10mg/kg
Description: anti-VEGF, a biosimilar to Avastin
Study: NCT00910494

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Radiosurgery System IORT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Radiosurgery System IORT
Study: NCT03322982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: less than 20% calories from fat daily
Study: NCT03448016

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOP-1A
Description: Tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOP-1A
Description: Tracer
Study: NCT03816722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo2
Description: Treatment with HighFlow through the Airvo2 device, 8 hours per day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airvo2
Description: Treatment with HighFlow through the Airvo2 device, 8 hours per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients
Study: NCT00049257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered Day 1 of each cycle. AUC=6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: administered Days 1, 8, and 15 of each cycle. 100mg/m2
Study: NCT05271747

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AB-Kolicare
Description: Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reuteri gotas
Description: Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
Study: NCT04244266

Intervention type: OTHER
Intervention: NO INTERVENTION, it is an observational study
Description: No intervention

Intervention type: OTHER
Intervention: NO INTERVENTION, it is an observational study
Description: No intervention

Intervention type: OTHER
Intervention: NO INTERVENTION, it is an observational study
Description: No intervention
Study: NCT04092114

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHARISMA Intervention
Description: SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning
Study: NCT04044014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gellan sheet
Description: Gellan sheet.
Study: NCT02036424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: intravitreal steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: antiVEGF
Study: NCT01532570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
Study: NCT03890393

Intervention type: DEVICE
Intervention: Electromyography
Description: Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.

Intervention type: DEVICE
Intervention: Electromyography
Description: Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.

Intervention type: DEVICE
Intervention: Electromyography
Description: Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
Study: NCT03057951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily